DRUGS & PHARMACEUTICALS LTD.

MANUFACTURER OF
BULK DRUGS &
IMPORTERS OF
SOLVENTS & CHEMICALS

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ✆ : (022) 23455543 Email: corporate@aareydrugs.com
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ✆ (02525) 271049 Email: info@aareydrugs.com
CIN:L99999MH1990PLC056538

Date: 14th November, 2026

To,

BSE Limited The Manager, Corporate Service Department P.J. Towers, Dalal Street, Mumbai- 400 001 **Scrip Code: 524412**	**National Stock Exchange of India Limited** Exchange Plaza BandraKurla Complex, Bandra (E), Mumbai – 400051 **NSE Symbol: AAREYDRUGS**

Sub: Outcome of Board Meeting held on today i.e 14th November, 2026

Ref: Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015('SEBI Listing Regulations').

Dear Sir/Madam,

This is to inform you that a meeting of the board of directors of the company was held today i.e. on Saturday, 14th November, 2026 at the registered office of the company, inter alia, to consider and take on record the Un-Audited Financial Results (on standalone basis) of the company for the second quarter & half year ended on 30th September, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and basis recommendation of the Audit Committee has, inter alia, approved the following.

1. The Board of Directors of the Company has considered and approved the Standalone Unaudited Financial Results for the second quarter & half year ended on 30th September, 2026 along with the Limited Review Report, MD/CFO certification.

2. Statement of Deviation or Variation in Utilization of Funds Raised through Convertible Warrants (Preferential Issue).

Kindly find attached herewith a copy of the Un-Audited standalone financial results along with Limited Review Report of the company for the second quarter & half year ended on 30th September, 2026, and Statement of Deviation or Variation.

Further, please note that in terms of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window of the Company will be open after 48 hours after the announcement of the said results.

Aarey
DRUGS & PHARMACEUTICALS LTD.

MANUFACTURER OF
BULK DRUGS &
IMPORTERS OF
SOLVENTS & CHEMICALS

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ✆ : (022) 23455543 Email: corporate@aareydrugs.com
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ✆ (02525) 271049 Email: info@aareydrugs.com
CIN:L99999MH1990PLC056538

Board meeting commenced at 4.00 P.M and concluded at 5.30 P.M.

Kindly take the same on your record and oblige.

For **Aarey Drugs & Pharmaceuticals Limited**

Nimit Rajesh Ghatalia
Digitally signed by Nimit Rajesh Ghatalia
Date: 2026.11.14 18:33:08 +05'30'

Nimit R. Ghatalia
Director
DIN: 07069841

Independent Auditor's Review Report On The Quarterly And Year To Date Unaudited Financial Results Of The Company Pursuant To The Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, as Amended

To,
The Board of Directors,
Aarey Drugs and Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited Financial Results of **Aarey Drugs and Pharmaceuticals Limited** ("the Company") for the quarter and half year ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended ("the listing Regulations").

2. The Company's management is responsible for preparation of the statement in the accordance with the recognition and measurement and principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim financial reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Director. Our responsibility is to express conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We draw attention to note no.5 of the Statement where the Company has stated that it has purchased certain fixed assets during the reporting period; however, these assets are not yet ready for their intended use as of the period end. Accordingly, no depreciation has been charged on these assets for the current period. Depreciation will commence once the assets are fully installed, commissioned, and available for use in accordance with IND AS 16.

For Motilal & Associates LLP
(a member firm of M A R C K S Network)
Chartered Accountants
ICAI FRN: 106584W/W100751

Motilal Hukumchand Jain
Digitally signed by Motilal Hukumchand Jain
Date: 2026.11.14 17:22:53 +05'30'

CA Motilal Jain
Partner
Membership No.: 036811

Place : Mumbai
Date : **14th November, 2026**

UDIN: 26036811AWRWES5154

Aarey
DRUGS & PHARMACEUTICALS LTD.

MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICAL & SOLVENTS

GST No. : 27AAACA5253A1Z9
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP. TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E-34, M.I.D.C.TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

AAREY DRUGS & PHARMACEUTICALS LTD

CIN: L99999MH1990PLC056538

Statement of Assets and Liabilities as at September 30, 2026

(Rs. In Lakhs)

Particulars	As at September 30, 2026	As at March 31, 2026
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	2142.90	1,766.26
Capital work-in-progress	235.70	811.58
Financial Assets		
Investments	211.50	211.50
Loans & Advances	-	-
Other Financial Assets	556.63	641.10
Deferred tax assets (net)	4.56	-
Other Non Current Assets	-	-
Total Non-current assets	**3,151.29**	**3,430.44**
Current assets		
Inventories	4,510.17	4,153.62
Financial Assets		
Trade Receivables	13,633.06	12,965.47
Cash and Cash Equivalents	135.63	139.86
Loans & Advances	2,690.88	2,060.45
Other Financial Assets	663.14	199.94
Income Tax Assets (net)	-	-
Other Current Assets	6,675.92	6,774.88
Total current assets	**28,308.81**	**26,294.23**
Total assets	**31,460.10**	**29,724.67**
EQUITY AND LIABILITIES		
Equity		
Equity Share Captial	3,197.43	2,845.43
Other Equity	13,480.08	11,820.39
Money received against share warrants	288.50	376.50
Total Equity	**16,966.01**	**15,042.32**
Liabilities		
Non-Current Liabilities		
Deferred Tax Liabilities	-	77.29
Financial Liabilities		
Borrowings	70.13	97.40
Trade Payables	-	-
Total Non Current Liabilities	**70.13**	**174.69**

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

Current liabilities		
Financial Liabilities		
Borrowings	5,559.05	4,898.76
Trade Payables :-		
Total outstanding dues of micro enterprises and small enterprises	-	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	6,810.68	8,158.90
Other Financial Liabilities	0.10	0.10
Provisions	385.52	1,078.71
Other Current Liabilities	1,608.62	211.94
Current Tax Liabilities	60.00	159.25
Total Current Liabilities	**14,423.96**	**14,507.66**
Total Equity and Liabilities	**31,460.10**	**29,724.67**

By order of the Board of Directors
For Aarey Drugs & Pharmaceuticals Limited

Place: Mumbai
Date: 14th November, 2026

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

Nhatalia.

Nimit Ghatalia
Director
DIN : 07069841

Aarey
DRUGS & PHARMACEUTICALS LTD.

MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICAL & SOLVENTS

GST No. : 27AAACA5253A1Z9
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP. TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E-34, M.I.D.C.TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

AAREY DRUGS & PHARMACEUTICALS LTD
CIN: L99999MH1990PLC056538
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30TH SEPTEMBER, 2026

(Rs. In Lakhs except EPS)

Particulars	Quarter ended			Half-Year Ended		Year Ended
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from Operations	8,862.44	4,462.55	8,416.20	13,324.99	18,637.03	47,226.90
Other Income	161.86	171.50	79.26	333.36	234.44	609.71
TOTAL INCOME	**9,024.30**	**4,634.05**	**8,495.47**	**13,658.35**	**18,871.48**	**47,836.61**
EXPENSES						
Cost of Materials Consumed	8,783.65	4,347.76	7,889.42	13,131.42	17,196.21	45,056.29
Changes in Inventories of Finished goods, Work in progress and Stock in trade	(224.20)	(132.35)	158.88	(356.55)	635.66	394.41
Employee Benefit Expenses	15.47	16.34	18.52	31.81	32.36	75.90
General Administrative Expense	18.02	17.95	32.24	35.97	49.19	92.81
Selling and Distribution Expense	5.69	34.62	10.04	40.31	49.93	397.46
Depreciation and Amortization Expense	94.42	85.02	69.26	179.44	118.09	285.30
Finance Cost	115.60	167.44	126.04	283.04	229.80	500.18
Other Expenses	49.68	45.70	42.87	95.38	239.20	492.84
TOTAL EXPENSES	**8,858.34**	**4,582.48**	**8,347.27**	**13,440.83**	**18,550.44**	**47,295.19**
Profit Before Exceptional Items and Tax	**165.96**	**51.56**	**148.20**	**217.52**	**321.04**	**541.42**
Exceptional Items	-	-	-	-	-	-
Profit / (Loss) Before Tax	**165.96**	**51.56**	**148.20**	**217.52**	**321.02**	**541.42**
Tax Expenses	**28.95**	**(50.81)**	**(45.82)**	**(21.85)**	**(81.51)**	**144.66**
a) Short/(excess) provision of earlier years		-				-
b) Current Tax	30.00	30.00	(35.00)	60.00	(70.00)	159.25
c) Deferred Tax	(1.05)	(80.81)	(10.82)	(81.85)	(11.51)	(14.59)
Profit / (Loss) for the period from continuing operations	**137.01**	**102.37**	**102.38**	**239.38**	**239.51**	**396.76**
Profit/(loss) from discontinued operations	-	-	-	-	-	-
Tax expense of discontinued operations	-	-	-	-	-	-

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

Profit/(loss) from Discontinued operations (after tax)		-	-	-	-	-
Profit/(loss) for the period	137.01	102.37	102.38	239.38	239.51	396.76
Other Comprehensive Income		-	-	-	-	-
Total Comprehensive Income for the year	137.01	102.37	102.38	239.38	239.51	396.76
Earnings per equity share : (of Rs. 10/- each) (for the period/year): *						
a) Basic EPS (Rs.)	0.43	0.36	0.36	0.75	0.85	1.39
b) Diluted EPS (Rs.)	0.43	0.36	0.36	0.75	0.85	1.39
Number of Shares	31,974,303	28,454,303	28,454,303	31,974,303	28,054,303	28,454,303
Percentage of Shareholding	100%	100%	100%	100%	100%	100%
Paid-up Equity Share Capital (FV of Rs. 10/- each) (incl. forfeited shares)	3,197.43	2,845.43	2,845.43	3,197.43	2,805.43	2,845.43

*Not Annualised

1. The above unaudited Financial results of the Company for the quarter ended 30th September, 2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on 14th November,2026.

Companies (Indian Accounting Standard) Rules, 2015 as prescribed under Secüon 133 of the Comparúes Act, 2013 read with the relavant rules issued thereunder and in terms of Regulation 33 and Regulation 52 of SEBI (Listing, Obligation and disclosure Requirements) Relations, 2015.

3. The Company operates only in one segment In Manufacturing and Trading of Drugs & Pharmaceutical and all other allied activities revolving around the same. As such there is no other separate reportable segment as defined by IND AS 108 -"Operating Segments"

4. The Figures of the previous year and/or period(s) have been regrouped wherever necessary.

5. The Company has purchased certain fixed assets during the reporting period; however, these assets are not yet ready for their intended use as of the period end. Accordingly, no depreciation has been charged on these assets for the current period. Depreciation will commence once the assets are fully installed, commissioned, and available for use in accordance with IND AS 16.

By Order of the Board of Directors
For Aarey Drugs and Pharmaceuticals Limited

Date: 14th November, 2026
Place: Mumbai

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

Nimit Ghatalia.

Nimit Ghatalia
Director
DIN : 07069841

Aarey
DRUGS & PHARMACEUTICALS LTD.

MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICAL & SOLVENTS

GST No. : 27AAACA5253A1Z9
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP, TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E-34, M.I.D.C.TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

AAREY DRUGS & PHARMACEUTICALS LTD

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30,2026

	Particulars	For the Half Year ended September 30	For the Half Year ended September 30
A.	**Cash Flow from Operating Activities**		
	Net profit before Tax as per Profit & Loss Account	217.52	321.02
	Adjusted for:		
	Depreciation	179.44	118.09
	Finance Cost	283.04	229.80
	Operating Profit before Working Capital Changes	680.01	668.91
	Adjusted for:		
	(Increase)/ Decrease in Inventories	(356.55)	635.66
	(Increase)/ Decrease in Trade receivables	(667.59)	1,112.85
	(Increase)/ Decrease in Other Current Loans and advances	(630.44)	406.56
	(Increase)/ Decrease in Other Current Financial assets	(463.20)	75.73
	(Increase)/ Decrease in Other Current assets	98.96	(734.25)
	Increase/ (Decrease) in Provision	(693.19)	86.79
	Increase/ (Decrease) in current tax liabilities	(160.30)	(140.19)
	Increase/ (Decrease) in Trade Payables	(1,348.22)	(1,968.66)
	Increase/ (Decrease) in Short Term Borrowings	660.29	1,664.69
	Increase/ (Decrease) in Other Current Liabilities	1,396.67	(348.23)
	Increase/ (Decrease) in Other financial liabilities	-	-
		(2,163.56)	790.95
	Less: Taxes Paid		-
	Cash Flow from Operating Activities (A)	(1,483.55)	1,459.84
B.	**Cash Flow from Investing Activities**		
	Purchase of Fixed Assets	20.84	(1,004.94)
	FD with Banks	-	-
	Maturity of Fixed deposits	-	-
	Sale of F.A.	-	-
	Net Cash used in Investing Activities (B)	20.84	(1,004.94)

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

C.	**Cash Flow from Financing Activities**		
	Issue of Equity share Capital	352.00	-
	Repayment Received of long term loans & advances	-	(378.41)
	Long term loans and advances given	-	-
	Deposits made	84.47	-
	Long term loans taken from banks	(27.27)	(72.40)
	Dividend Paid	-	-
	Preferential issue of equity shares	-	-
	Money received against share warrants	(88.00)	125.00
	Security Premium on Issue of Shares	1,420.32	672.50
	Finance Cost	(283.04)	(229.80)
	Right Issue Expense	-	-
	Net Cash used in Financing Activities (C)	**1,458.48**	**116.89**
	Net Increase/(Decrease) in Cash and Cash Equivalents (A +	**(4.24)**	**571.79**
	Opening Balance of Cash and Cash Equivalents	139.86	147.33
	Closing Balance of Cash and Cash Equivalents	**135.63**	**719.12**

Notes:

1 The above Cash flow Statement has been prepared under the "Indirect Method"set out in Ind AS-7 on Statement of Cash flow.

2 Previous year figures have been reclassified to confirm with current Year's presentation,wherever applicable.

3 This is the cashflows Statement reffered to in our report of even date.

By Order of the Board of Directors
For Aarey Drugs and Pharmaceuticals Limited

Nhatalia

Nimit Ghatalia
Director
DIN : 07069841

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

Date: 14th November, 2026
Place : Mumbai

Aarey
DRUGS & PHARMACEUTICALS LTD.

MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICAL & SOLVENTS

GST No. : 27AAACA5253A1Z9
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP. TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E-34, M.I.D.C.TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

Certificate of Managing Director (MD)

I, Mihir R. Ghatalia, Managing Director (MD) of Aarey Drugs & Pharmaceuticals Ltd., certify;

1. That I have reviewed the Unaudited Financial Statements for the Second quarter & half year ended 30th September, 2026 and to the best of my knowledge and belief:

   a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and

   b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.

2. That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.

3. That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

Mihir R. Ghatalia
Managing Director

Date: 14th November 2026

Place: Mumbai

Aarey
DRUGS & PHARMACEUTICALS LTD.

MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICAL & SOLVENTS

GST No. : 27AAACA5253A1Z9
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP. TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E-34, M.I.D.C.,TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

Certificate of Chief Financial Officer (CFO)

I, Mira M. Ghatalia, Chief Financial Officer (CFO) of Aarey Drugs & Pharmaceuticals Ltd., certify;

1. That I have reviewed the Unaudited Financial Statements for the Second quarter & half year ended 30th September, 2026 and to the best of my knowledge and belief:

   a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and

   b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.

2. That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.

3. That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.

M M Ghatalia

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

Mira M. Ghatalia
Chief Financial Officer

Date: 14th November 2026

Place: Mumbai

Aarey
DRUGS & PHARMACEUTICALS LTD.

MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICAL & SOLVENTS

GST No. : 27AAACA5253A1Z9
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP. TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E-34, M.I.D.C.,TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

Date: 14th November, 2026

To,

BSE Limited The Manager, Corporate Service Department P.J. Towers, Dalal Street, Mumbai- 400 001 **Scrip Code: 524412**	**National Stock Exchange of India Limited** Exchange Plaza BandraKurla Complex, Bandra (E), Mumbai – 400051 **NSE Symbol: AAREYDRUGS**

Sub: Statement of Deviation or variation in utilization of Funds.

Dear Sir/Madam,

Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Statement of Deviation or Variation in utilisation of funds raised through Conversion of Warrants into Equity Shares for the Second quarter and half year ended September 30, 2026.

This is for your information and records.

Thanking you,

Yours faithfully

For **Aarey Drugs & Pharmaceuticals Limited**

Nimit R. Ghatalia
Director
DIN: 07069841

Aarey
DRUGS & PHARMACEUTICALS LTD.

MANUFACTURER OF
BULK DRUGS &
IMPORTERS OF
SOLVENTS & CHEMICALS

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ✆ : (022) 23455543 Email: corporate@aareydrugs.com
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ✆ (02525) 271049 Email: info@aareydrugs.com
CIN:L99999MH1990PLC056538

STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Statement on deviation / variation in utilisation of funds raised	
Name of Listed Entity	Aarey Drugs & Pharmaceuticals Limited
Mode of Fund Raising (Public Issues / Rights Issues / Preferential Issues / QIP / Others)	Convertible Warrants – Preferential Basis ("Preferential Issue")
Date of Raising Funds	23/05/2025 (Date of Allotment) 06.08.2026 30.09.2026
Amount Raised	₹2,481.82 Lakhs received up to 30.09.2026, out of the total issue size of ₹3,190.00 Lakhs, comprising: (i) ₹797.50 Lakhs (25%) received on allotment of warrants on 23.05.2025; and (ii) ₹1,684.32 Lakhs (75% balance consideration) received on conversion of 35,20,000 warrants during the quarter (₹1,205.82 Lakhs on 06.08.2026 and ₹478.50 Lakhs on 30.09.2026).
Report filed for Quarter ended	30-09-2026
Monitoring Agency applicable / not applicable	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	Nil
Objects for which funds have been raised and where there has been a deviation, in the following table	–

Aarey
DRUGS & PHARMACEUTICALS LTD.

MANUFACTURER OF
BULK DRUGS &
IMPORTERS OF
SOLVENTS & CHEMICALS

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ✆ : (022) 23455543 Email: corporate@aareydrugs.com
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ✆ (02525) 271049 Email: info@aareydrugs.com
CIN:L99999MH1990PLC056538

Original Object	Modified Object, if any	Original Allocation (₹ in Lakhs)	Modified allocation, if any	Funds Utilised (₹ in Lakhs)	Amount of Deviation / Variation for the quarter according to applicable object	Remarks if any
The Company as a part of its financial strategy proposes to offer, issue and allot Convertible Warrants to its Promoter/Non Promoter/Promoter group member on preferential basis, for infusing additional funds in the Company which may be employed in the business of the Company and/or may be used to augment the funding needs for re-structuring/settlement of liabilities/debts and/or such other appropriate arrangements and/or understanding with Bankers and/or other Creditors and/or investment in technology and/or for general corporate purposes which shall enhance the business of the Company and for any other purpose as may be decided and approved by the Board.	Nil	3,190.00	Nil	2,081.82	Nil	50,00,000 Convertible Warrants were allotted on 23.05.2025 at ₹63.80 per warrant (aggregating ₹3,190.00 Lakhs). 25% (₹797.50 Lakhs) was received on allotment and utilised for the stated objects, as reported in the statement for the year ended 31.03.2026. During the quarter ended 30.09.2026, 35,20,000 warrants were converted into equity shares and the balance 75% consideration of ₹1,684.32 Lakhs was received on conversion. Unutilised proceeds of ₹400.00 Lakhs as on 30.09.2026 are lying in Company's bank account pending utilisation for the stated objects.
Total		**3,190.00**		**2,081.82**	**Nil**	

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

Aarey
DRUGS & PHARMACEUTICALS LTD.

MANUFACTURER OF
BULK DRUGS &
IMPORTERS OF
SOLVENTS & CHEMICALS

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ✆ : (022) 23455543 Email: corporate@aareydrugs.com
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ✆ (02525) 271049 Email: info@aareydrugs.com
CIN:L99999MH1990PLC056538

For and on behalf of the Board of Directors
Aarey Drugs & Pharmaceuticals Limited

Name of Signatory: Mira Mihir Ghatalia
Designation: Chief Financial Officer

MMG Ghatalia

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

Date: 14th November, 2026
Place: Mumbai